16487617

Source:http://linkedlifedata.com/resource/pubmed/id/16487617

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003451, umls-concept:C0017431, umls-concept:C0030705, umls-concept:C0031327, umls-concept:C0036043, umls-concept:C0086418, umls-concept:C0162768, umls-concept:C0220825, umls-concept:C0282460, umls-concept:C0441655, umls-concept:C0524910
pubmed:issue	4
pubmed:dateCreated	2006-3-17
pubmed:abstractText	Recombinant human albumin-interferon alfa (alb-IFN) is a novel 85.7-kD recombinant protein consisting of interferon alfa-2b genetically fused to human serum albumin.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8503886
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Serum Albumin, http://linkedlifedata.com/resource/pubmed/chemical/albuferon
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0168-8278
pubmed:author	pubmed-author:BainVincent GVG, pubmed-author:CroninPatrick WPW, pubmed-author:FiscellaMicheleM, pubmed-author:FreimuthWilliam WWW, pubmed-author:HeathcoteE JennyEJ, pubmed-author:KaitaKelly DKD, pubmed-author:McHutchisonJohn GJG, pubmed-author:NeumannAvidan UAU, pubmed-author:OsbornBlaire LBL, pubmed-author:SubramanianG ManiGM, pubmed-author:SwainMark GMG, pubmed-author:YoshidaEric MEM, pubmed-author:YuRenR
pubmed:issnType	Print
pubmed:volume	44
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	671-8
pubmed:meshHeading	pubmed-meshheading:16487617-Adult, pubmed-meshheading:16487617-Arthralgia, pubmed-meshheading:16487617-Chills, pubmed-meshheading:16487617-Dose-Response Relationship, Drug, pubmed-meshheading:16487617-Drug Tolerance, pubmed-meshheading:16487617-Fatigue, pubmed-meshheading:16487617-Female, pubmed-meshheading:16487617-Genotype, pubmed-meshheading:16487617-Half-Life, pubmed-meshheading:16487617-Headache, pubmed-meshheading:16487617-Hepacivirus, pubmed-meshheading:16487617-Hepatitis C, Chronic, pubmed-meshheading:16487617-Humans, pubmed-meshheading:16487617-Injections, Subcutaneous, pubmed-meshheading:16487617-Interferon-alpha, pubmed-meshheading:16487617-Male, pubmed-meshheading:16487617-Middle Aged, pubmed-meshheading:16487617-RNA, Viral, pubmed-meshheading:16487617-Recombinant Proteins, pubmed-meshheading:16487617-Serum Albumin
pubmed:year	2006
pubmed:articleTitle	A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
pubmed:affiliation	University of Alberta, Liver Unit, Zeidler Ledcor Center, 130 University Campus, Edmonton, Alberta, Canada, T6G 2X8. vince.bain@ualberta.ca
pubmed:publicationType	Journal Article, Clinical Trial, Phase II